Avinger (NASDAQ:AVGR) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR) in a report issued on Saturday morning. The brokerage issued a hold rating on the medical device company’s stock.

Avinger Price Performance

NASDAQ AVGR opened at $0.97 on Friday. Avinger has a 1-year low of $0.39 and a 1-year high of $5.45. The business’s fifty day moving average price is $0.82 and its 200-day moving average price is $1.16. The stock has a market capitalization of $3.19 million, a price-to-earnings ratio of -0.09 and a beta of 1.14.

Avinger (NASDAQ:AVGR) last posted its quarterly earnings data on Thursday, November 7th. The medical device company reported ($1.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.21. The company had revenue of $1.65 million for the quarter, compared to the consensus estimate of $1.60 million. Avinger had a negative net margin of 261.06% and a negative return on equity of 5,527.11%. During the same quarter last year, the firm posted ($2.92) earnings per share. Equities research analysts anticipate that Avinger will post -4.69 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Avinger stock. Armistice Capital LLC bought a new stake in shares of Avinger, Inc. (NASDAQ:AVGR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned approximately 2.57% of Avinger as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 18.30% of the company’s stock.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.